Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who received a dual cord blood transplant are eligible and must have achieved donor cord blood chimerism of \> 75% in both T-cell and myeloid lineages~* At the time of thymus transplantation, subjects cannot have active grade II-IV acute graft versus host disease.~* At the time of thymus transplantation, the subject must have an absolute neutrophil count of \> 500/ul and a platelet count of 50,000/ul (even if achieved via transfusion).~* At the time of thymus transplantation, the subject must have \< or equal to 50 circulating CD 34+ cells/ul (as measured within 3 weeks of transplant date).~* At the time of thymus transplantation, subjects cannot be on greater than 2 mg/kg/day methylprednisolone or its equivalent of steroids.~* At the time of thymus transplantation, PT and PTT must be less that 1.5 times the ULN or must be correctable to this level.~* At the time of thymus transplantation, subjects cannot require oxygen or have pulmonary disease that would be thought to make general anesthesia a high risk.~* Subjects must be between the ages of 18 and 60 years of age.~Exclusion Criteria:~* Subjects cannot have bone marrow flow cytometry demonstrating residual leukemia~* Subjects cannot have insufficient subcutaneous tissue and muscle mass to be able to accept and heal a thymus transplant, as assessed by a surgeon.~* Prior to thymus transplantation, subjects cannot have evidence of active disease with HHV6, West Nile Virus, EBV, and CMV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): Thymic tissue from third party donor

Based on this trial design, predict the completion outcome and termination type (if applicable).